Recent alcohol consumption and risk of incident ovarian carcinoma: A pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kelemen, Linda E ^a   Bandera, Elisa V ^b   Terry, Kathryn L ^c,d   Rossing, Mary Anne ^e   Brinton, Louise A ^f   Doherty, Jennifer A ^e   Ness, Roberta B ^g   Kjær, Susanne Krüger ^h,i   Chang Claude, Jenny ^j   Köbel, Martin ^k   Lurie, Galina ^l   Thompson, Pamela J ^l   Carney, Michael E ^l   Moysich, Kirsten ^m   Edwards, Robert ⁿ   Bunker, Clare ^o   Jensen, Allan ^h   Høgdall, Estrid ^h   Cramer, Daniel W ^c,d   Vitonis, Allison F ^c   Olson, Sara H ^p   King, Melony ^b   Chandran, Urmila ^b   Lissowska, Jolanta ^q   Garcia Closas, Montserrat ^r   Yang, Hannah ^f   Webb, Penelope M ^s   Schildkraut, Joellen M ^t   Goodman, Marc T ^l,u   Risch, Harvey A ^v   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e USA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^h DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k CALGARY LABORATORY SERVICES   (Canada)

^l UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

^o UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q INSTITUTE OF ONCOLOGY   (Poland)

^r INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^s QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^t DUKE UNIVERSITY MEDICAL CENTER   (United States)

^u CEDARS SINAI MEDICAL CENTER   (United States)

^v YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NORTH AMERICA; OVARY CARCINOMA; RISK ASSESSMENT; RISK REDUCTION; SMOKING; WINE;

ALCOHOL DRINKING; ALCOHOLIC BEVERAGES; AUSTRALIA; CANADA; CARCINOMA; CASE-CONTROL STUDIES; EUROPE; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; ODDS RATIO; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84872438730     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-28     Document Type: Article

References (89)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. Lynch HT, Schuelke GS, Kimberling WJ, Albano WA, Lynch JF, Biscone KA, Lipkin ML, Deschner EE, Mikol YB, Sandberg AA, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 1985, 56(4):939-951. 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T, 4016686.
3. Lynch HT, Conway T, Lynch J. Hereditary ovarian cancer. Pedigree studies, Part II. Canc Genet Cytogenet 1991, 53(2):161-183.
4. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997, 64(2):196-206. 10.1006/gyno.1996.4572, 9038264.
5. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA. Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994, 74(8):2341-2346. 10.1002/1097-0142(19941015)74:8<2341::AID-CNCR2820740819>3.0.CO;2-Z, 7922985.
6. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001, 68(3):700-710. 10.1086/318787, 1274482, 11179017.
7. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41(9):996-1000. 10.1038/ng.424, 2844110, 19648919.
8. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010, 42(10):874-879. 10.1038/ng.668, 3020231, 20852632.
9. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010, 42(10):880-884. 10.1038/ng.666, 3125495, 20852633.
10. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992, 80(4):708-714.
11. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987, 316(11):650-655.
12. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative ovarian cancer group. Am J Epidemiol 1992, 136(10):1184-1203.
13. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994, 140(7):585-597.
14. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol 2005, 96(2):520-530. 10.1016/j.ygyno.2004.10.037, 15661246.
15. Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, Hankinson SE. Prospective study of talc use and ovarian cancer. J Natl Canc Inst 2000, 92(3):249-252.
16. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res 2003, 23(2C):1955-1960.
17. Kelemen LE, Sellers TA, Vierkant RA, Harnack L, Cerhan JR. Association of folate and alcohol with risk of ovarian cancer in a prospective study of postmenopausal women. Canc Causes Contr 2004, 15(10):1085-1093.
18. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, Fraser GE, Freudenheim JL, Goldbohm RA, et al. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Canc Epidemiol Biomarkers Prev 2006, 15(2):364-372.
19. Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, Sellers TA. Prospective study of diet and ovarian cancer. Am J Epidemiol 1999, 149(1):21-31. 10.1093/oxfordjournals.aje.a009723, 9883790.
20. Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001, 92(9):2318-2326. 10.1002/1097-0142(20011101)92:9<2318::AID-CNCR1578>3.0.CO;2-7, 11745286.
21. Schulz M, Lahmann PH, Boeing H, Hoffmann K, Allen N, Key TJ, Bingham S, Wirfalt E, Berglund G, Lundin E, et al. Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition. Canc Epidemiol Biomarkers Prev 2005, 14(11 Pt 1):2531-2535.
22. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996, 144(4):363-372. 10.1093/oxfordjournals.aje.a008937, 8712193.
23. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012, 13(4):385-394. 10.1016/S1470-2045(11)70404-1, 22361336.
24. Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS. Cigarette smoking and risk of epithelial ovarian cancer. Canc Causes Contr 2008, 19(4):413-420.
25. Green A, Purdie D, Bain C, Siskind V, Webb PM. Cigarette smoking and risk of epithelial ovarian cancer (Australia). Canc Causes Contr 2001, 12(8):713-719.
26. Gwinn ML, Webster LA, Lee NC, Layde PM, Rubin GL. Alcohol consumption and ovarian cancer risk. Am J Epidemiol 1986, 123(5):759-766.
27. Webb PM, Purdie DM, Bain CJ, Green AC. Alcohol, wine, and risk of epithelial ovarian cancer.[see comment]. Canc Epidemiol Biomarkers Prev 2004, 13(4):592-599.
28. Riman T, Dickman PW, Nilsson S, Nordlinder H, Magnusson CM, Persson IR. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol 2004, 19(11):1011-1019. 10.1007/s10654-004-1633-8, 15648594.
29. Chang ET, Canchola AJ, Lee VS, Clarke CA, Purdie DM, Reynolds P, Bernstein L, Stram DO, Anton-Culver H, Deapen D, et al. Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. Canc Causes Contr 2007, 18(1):91-103.
30. Peterson NB, Trentham-Dietz A, Newcomb PA, Chen Z, Hampton JM, Willett WC, Egan KM. Alcohol consumption and ovarian cancer risk in a population-based case-control study. Int J Cancer 2006, 119(10):2423-2427. 10.1002/ijc.22137, 16921486.
31. Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 2008, 112(5):1169-1177. 10.1002/cncr.23275, 18213613.
32. La Vecchia C, Negri E, Franceschi S, Parazzini F, Gentile A, Fasoli M. Alcohol and epithelial ovarian cancer. J Clin Epidemiol 1992, 45(9):1025-1030. 10.1016/0895-4356(92)90119-8, 1432017.
33. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989, 161(1):10-16.
34. Modugno F, Ness RB, Allen GO. Alcohol consumption and the risk of mucinous and nonmucinous epithelial ovarian cancer. Obstet Gynecol 2003, 102(6):1336-1343. 10.1016/j.obstetgynecol.2003.08.008, 14662224.
35. Kuper H, Titus-Ernstoff L, Harlow BL, Cramer DW. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer 2000, 88(2):313-318. 10.1002/1097-0215(20001015)88:2<313::AID-IJC26>3.0.CO;2-5, 11004686.
36. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Harnack L, Hankinson SE, Larsson SC, et al. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer 2006, 94(5):757-762. 2361197, 16495916.
37. Kelemen LE, Goode EL. Alcohol intake increases risk of mucinous epithelial ovarian cancer: a meta-analysis. Am J Epidemiol 2007, 165(suppl):S89. Abstract #355.
38. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, Negri E, Boffetta P, Bellocco R, Corrao G, et al. Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis. Gynecol Oncol 2012, 125(3):758-763. 10.1016/j.ygyno.2012.03.031, 22449732.
39. Schouten LJ, Zeegers MP, Goldbohm RA, van den Brandt PA. Alcohol and ovarian cancer risk: results from the Netherlands Cohort Study. Canc Causes Contr 2004, 15(2):201-209.
40. Phillips CV. Publication bias in situ. BMC Med Res Methodol 2004, 4:20. 10.1186/1471-2288-4-20, 514545, 15296515.
41. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5(12):e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
42. Wong KK, Gershenson D. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers 2007, 23(5-6):377-387.
43. Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and increased risk of epithelial ovarian cancer. Canc Epidemiol Biomarkers Prev 2006, 15(9):1738-1741.
44. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Canc Epidemiol Biomarkers Prev 2007, 16(12):2548-2556.
45. Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME. Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Canc 2008, 15(4):1055-1060.
46. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011, 21(3):188-196. 10.1016/j.annepidem.2010.10.002, 3052991, 21109450.
47. Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One 2010, 5(4):e10061. 10.1371/journal.pone.0010061, 2851649, 20386703.
48. Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Canc Epidemiol Biomarkers Prev 2008, 17(3):585-593.
49. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005, 65(13):5974-5981. 10.1158/0008-5472.CAN-04-3885, 1364476, 15994977.
50. Terry KL, Tworoger SS, Goode EL, Gates MA, Titus-Ernstoff L, Kelemen LE, Sellers TA, Hankinson SE, Cramer DW. MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol Oncol 2010, 119(2):319-324. 10.1016/j.ygyno.2010.08.007, 2952716, 20817226.
51. Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health 2011, 11:40. 10.1186/1472-6874-11-40, 3196697, 21943063.
52. Chandran U, Bandera EV, Williams-King MG, Paddock LE, Rodriguez-Rodriguez L, Lu SE, Faulkner S, Pulick K, Olson SH. Healthy eating index and ovarian cancer risk. Canc Causes Contr 2011, 22(4):563-571.
53. Risch HA, Jain M, Marrett LD, Howe GR. Dietary fat intake and risk of epithelial ovarian cancer. J Natl Canc Inst 1994, 86(18):1409-1415.
54. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001, 95(6):370-374. 10.1002/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T, 11668519.
55. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004, 164(20):2253-2259. 10.1001/archinte.164.20.2253, 15534163.
56. Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK, Blaakaer J, Kjaer SK. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Canc Causes Contr 2006, 17(6):821-829.
57. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Canc Epidemiol Biomarkers Prev 2007, 16(6):1160-1166.
58. Garcia-Closas M, Brinton LA, Lissowska J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Zatonski W, et al. Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. BMC Canc 2007, 7:60.
59. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008, 122(1):170-176. 10.1002/ijc.23017, 17721999.
60. Ibiebele TI, Parekh S, Mallitt KA, Hughes MC, O'Rourke PK, Webb PM. Reproducibility of food and nutrient intake estimates using a semi-quantitative FFQ in Australian adults. Publ Health Nutr 2009, 12(12):2359-2365.
61. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999, 9(3):178-187. 10.1016/S1047-2797(98)00055-6, 10192650.
62. Hankin JH, Wilkens LR, Kolonel LN, Yoshizawa CN. Validation of a quantitative diet history method in Hawaii. Am J Epidemiol 1991, 133(6):616-628.
63. Willett W, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122(1):51-65.
64. Rothman KJ, Greenland S. Modern epidemiology 1998, Philadelphia, PA: Lippincott-Reaven Publishers, 2.
65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
66. Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, Bernstein L, Berrino F, van den Brandt PA, Buring JE, Cho E, et al. Methods for pooling results of epidemiologic studies: the pooling project of prospective studies of diet and cancer. Am J Epidemiol 2006, 163(11):1053-1064. 10.1093/aje/kwj127, 16624970.
67. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986, 124(1):17-27.
68. Hosmer DW, Lemeshow SL. Applied logistic regression 2000, New York, NY: John Wiley and Sons, Inc.
69. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Kobel M, Anton-Culver H, Beesley J, Berchuck A, Brar S, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Canc Epidemiol Biomarkers Prev 2010, 19(7):1822-1830.
70. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003, 27(7):985-993. 10.1097/00000478-200307000-00014, 12826891.
71. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010, 29(3):203-211. 10.1097/PGP.0b013e3181c042b6, 20407318.
72. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008, 39(8):1239-1251. 10.1016/j.humpath.2008.01.003, 18602670.
73. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002, 287(19):2559-2562. 10.1001/jama.287.19.2559, 12020337.
74. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591.
75. Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25(5):346-354. 10.1080/08977190701838402, 18236213.
76. Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009, 22(3):469-475. 10.1038/modpathol.2008.206, 19136932.
77. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 2002, 33(8):801-805. 10.1053/hupa.2002.126186, 12203212.
78. Rosendahl AH, Holly JM, Celander M, Forsberg G. Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. Int J Cancer 2008, 123(6):1286-1291. 10.1002/ijc.23642, 18561321.
79. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012, 62(1):30-67. 10.3322/caac.20140, 22237782.
80. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007, 7(8):599-612.
81. World Cancer Research Fund/American Institute for Cancer Research Food, nutrition, physical activity, and the prevention of cancer: a global perspective 2007, Washington, DC: AICR, World Cancer Research Fund/American Institute for Cancer Research.
82. Goodman MT, Tung KH. Alcohol consumption and the risk of borderline and invasive ovarian cancer. Obstet Gynecol 2003, 101(6):1221-1228. 10.1016/S0029-7844(03)00050-4, 12798528.
83. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004, 79(5):727-747.
84. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005, 45(4):287-306. 10.1080/1040869059096, 16047496.
85. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, Folsom AR, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Canc Inst 2007, 99(10):801-810.
86. Gavallos G, Tawfik O, Herrell D, Langenstroer P. Renal-ovarian axis: a case report and review. Urology 2003, 62(4):749.
87. Matsumura N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamanishi J, Kang HS, Matsui S, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Canc Sci 2010, 101(12):2658-2663.
88. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11(18):6422-6430. 10.1158/1078-0432.CCR-05-0508, 16166416.
89. Risch HA. Hormone replacement therapy and the risk of ovarian cancer. Gynecol Oncol 2002, 86(2):115-117. 10.1006/gyno.2002.6774, 12144814.